Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

xanomeline-trospium

xanomeline-trospium
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Cobenfy CAPSULE, ORAL 50 mg-20 mg, 100 mg-20 mg    


Comments:

Formulary, restricted to psychiatrists for use in patients unresponsive to other oral antipsychotics.

 

Inpatients should use home supply if available. The 50 mg-20 mg and 100 mg-20 mg dosage forms will be stocked for inpatient use. For inpatients whose home supply is unavailable, the 125 mg-30 mg dose will be automatically interchanged to the 100 mg-20 mg dose.

 

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

xanomeline-trospium (Cobenfy)

  • xanomeline 125 mg-trospium 30 mg oral capsule                                              
  • Only interchange for inpatients whose home supply is unavailable                             

xanomeline-trospium (Cobenfy)

  • xanomeline 100 mg-trospium 20 mg oral capsule

 

Reviewed: February 2025

 

Xanomeline-trospium (Cobenfy) Spotlight


Last updated: Mar. 21, 2025







This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.